New drugs: Denosumab, dienogest/estradiol valerate, and polidocanol

J Am Pharm Assoc (2003). 2010 Sep-Oct;50(5):658-62. doi: 10.1331/JAPhA.2010.10536.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Contraceptive Agents / adverse effects
  • Contraceptive Agents / therapeutic use*
  • Denosumab
  • Estradiol / adverse effects
  • Estradiol / analogs & derivatives
  • Estradiol / therapeutic use
  • Female
  • Humans
  • Male
  • Nandrolone / adverse effects
  • Nandrolone / analogs & derivatives*
  • Nandrolone / therapeutic use
  • Osteoporosis, Postmenopausal / drug therapy*
  • Osteoporosis, Postmenopausal / prevention & control
  • Polidocanol
  • Polyethylene Glycols / adverse effects
  • Polyethylene Glycols / therapeutic use*
  • RANK Ligand / adverse effects
  • RANK Ligand / agonists
  • RANK Ligand / therapeutic use*
  • Sclerosing Solutions / adverse effects
  • Sclerosing Solutions / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Contraceptive Agents
  • RANK Ligand
  • Sclerosing Solutions
  • TNFSF11 protein, human
  • Polidocanol
  • Polyethylene Glycols
  • dienogest
  • Denosumab
  • Estradiol
  • Nandrolone